NCT07405970招募中3 期
A Phase 3 Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus.
Beijing Mabworks Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 316 人开始时间: 2026年4月10日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 316
- 试验地点
- 1
- 主要终点
- Percentage of participants achieving SRI-4 at Week 52
研究概览
简要总结
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-80 ;
- •Diagnosis of systemic lupus erythematosus according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria ;
- •Positive antinuclear antibodies (ANA) ≥ 1:80 at screening or positive anti- dsDNA ;
- •High disease activity at screening ,SLEDAI-2000 score ≥8 (excluding alopecia score);
- •On a stable dose of one or more standard treatments for SLE prior to the first administration；
- •Able and willing to provide written informed consent and to comply with the study protocol.
排除标准
- •Unsufficient organ function;
- •Received rituximab or any B-cell depleting drug within 9 months prior to the first dose;
- •Subjects with CD4+ T lymphocyte count < 200 cells/μL;
- •Received cyclophosphamide within 8 weeks prior to the first dose; received calcineurin inhibitors (cyclosporine, tacrolimus, etc., except for topical use) or plasma exchange therapy within 4 weeks prior to the first dose;
- •Received a B-cell stimulating factor inhibitor such as Belimumab, and Telitacicept within 8 weeks prior to the first administration;
- •TNF inhibitor, interleukin monoclonal antibody, JAK inhibitor, BTK inhibitor, TYK2 inhibitor, or thalidomide within 4 weeks prior to the first administration;
- •Received live or attenuated vaccination within 28 days prior to the first administration;
- •Participated in other clinical trials within 28 days prior to the first administration;
- •Concomitant with other serious diseases;
- •Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with HBV DNA titer above the normal range; positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV);
- •Subjects with known history of severe allergic reactions to humanized monoclonal antibodies MIL62;
- •Breastfeeding or pregnant women;
- •Childbearing potential and unwillingness or impossibility to comply with a scientifically acceptable birth-control method;
- •Other conditions unsuitable for participation in this study determined by the Investigator.
研究组 & 干预措施
MIL62
Experimental
干预措施: MIL62 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of participants achieving SRI-4 at Week 52
时间窗: at Week 52
次要结局
- Proportion of participants achieving SRI-4 at Week 24(at Week 24)
- Changes in 24-hour urine protein in patients with baseline 24-hour urine protein elevation (24-hour urine protein ≥0.5g) at Week 24, 52(at Week 24,52)
- Percentage of participants who achieved or maintained a prednisone dose of ≤7.5 mg/day (or equivalent dose) during Weeks 40 to 52(from Week 40 to Week 52 after randomization)
- Change From Baseline in EuroQol 5-Dimensional Questionnaire at Week 24, 52(up to 52 weeks after randomization)
- Change From Baseline in Serum Immunoglobulin Levels at Week 24 Change from baseline in the serum levels of IgG, IgA, IgM(up to 52 weeks after randomization)
- Change From Baseline in biomarkers associated with disease anti-dsDNA ,complement component 3 (C3), and complement component 4 (C4)(up to 52 weeks after randomization)
- Percentage of Participants with Adverse Events(up to 52 weeks after randomization)
- Pharmacodynamics(PD) characteristics: summarizing the changes in the absolute counts and percentages of peripheral blood CD19⁺ B cells(up to 52 weeks after randomization)
- Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL62(up to 52 weeks after randomization)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren SyndromeNCT07375524Shanghai Escugen Biotechnology Co., Ltd40
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150
招募中
2 期
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
招募中
1 期
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerNCT07281976Nanjing Leads Biolabs Co.,Ltd220